ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings
  • Abstract Number: 0051 • ACR Convergence 2024

    Impact of Tight Junction Proteins on Inflammatory Processes and Microbial Imbalance in Rheumatoid Arthritis

    Arkaitz Mucientes1, jose Manuel Lisbona-Montañez2, Patricia Ruiz-Limón3, Sara Manrique-Arija4, Aimara García-Studer4, Fernando Ortiz-Márquez4, Natalia Mena Vázquez5 and Antonio Fernández-Nebro6, 1IBIMA Plataforma BIONAND, Malaga, Andalucia, Spain, 2University of Malaga, Malaga, Andalucia, Spain, 3IBIMA, Instituto de Biomedicina de Málaga, Cordoba, Spain, 4Biomedical Research Institute of Malaga (IBIMA)-Bionand Platform, Department of Rheumatology, Regional University Hospital of Malaga, Malaga, Spain, 5IBIMA, Málaga, Andalucia, Spain, 6Department of Rheumatology, Hospital Universitario de Málaga, Málaga, Andalucia, Spain

    Background/Purpose: The etiology of Rheumatoid Arthritis (RA) is not fully understood. Recent studies point to intestinal permeability as an important factor in the establishment and…
  • Abstract Number: 0057 • ACR Convergence 2024

    Flow Cytometry of Cells Within Induced Sputum from Individuals At-Risk for RA Reveals Relative Expansion of Small Macrophages

    Hideto Takada1, Brian Hattel2, Marie Feser3, LauraKay Moss2, Yuko Okamoto4, Mark Gillespie5, Adam Savage5, Troy Torgerson6, V. Michael Holers7, Kevin Deane8 and Kristen Demoruelle9, 1Tokyo Women's Medical University, Denver, CO, 2University of Colorado Anschutz Medical Campus, Denver, CO, 3Division of Rheumatology, University of Colorado School of Medicine, Aurora, CO, 4Tokyo Women's Medical University Division of Rheumatology, Shinjyuku-ku, Tokyo, Japan, 5Allen Institute for Immunology, Seattle, WA, 6Allen Institute for Immunology, Enumclaw, WA, 7University of Colorado, Denver, CO, 8University of Colorado Denver Anschutz Medical Campus, Aurora, CO, 9University of Colorado Anschutz Medical Campus, Golden, CO

    Background/Purpose: Serum elevations of ACPA in the absence of inflammatory arthritis is a well-established risk factor for the future development of clinical RA. The lung…
  • Abstract Number: 0115 • ACR Convergence 2024

    Regional and Ethnoracial Differences Among Antiphospholipid Antibody-Positive Patients with No Other Systemic Autoimmune Rheumatic Diseases: Results from AntiPhospholipid Syndrome Alliance for Clinical Trials and InternatiOnal Networking (APS ACTION) Registry

    Elena Gkrouzman1, Ann E. Clarke2, Maria Tektonidou3, Vittorio Pengo4, Savino Sciascia5, Jose Pardos-Gea6, Nina Kello7, Diana Paredes-Ruiz8, Mª Angeles Aguirre-Zamorano9, H Michael Belmont10, Paul Fortin11, Guilherme Ramires de Jesús12, Tatsuya Atsumi13, Zhuoli Zhang14, Maria Efthymiou15, David Branch16, Giulia Pazzola17, Laura Andreoli18, Ali Duarte-Garcia19, Esther Rodriguez-Almaraz20, Michelle Petri21, Ricard Cervera22, Bahar Artim Esen23, Guillermo Pons-Estel24, Hui Shi25, Jason Knight26, Rohan Willis27, Pierluigi Meroni28, Maria Laura Bertolaccini29, Hannah Cohen30, Robert Roubey31, Danieli Andrade32 and Doruk Erkan33, and on behalf of APS ACTION, 1University of Massachusetts, Westborough, MA, 2Division of Rheumatology, Cumming School of Medicine, University of Calgary, Calgary, AB, Canada, 3National and Kapodistrian University of Athens, Athens, Greece, 4Thrombosis Research Laboratory, Department of Cardio-Thoracic-Vascular Sciences and Public Health, University of Padova, Padova, Italy, 5University of Turin, Torino, Turin, Italy, 6Vall d'Hebron University Hospital, Barcelona, Spain, 7Northwell Health, Brooklyn, NY, 8Autoimmune Diseases Research Unit. Biocruces Bizkaia Health Research Institute, Baracaldo, Spain, 9IMIBIC/Reina Sofia Hospital/University of Cordoba, CÓRDOBA, Andalucia, Spain, 10NYU School of Medicine, New York, NY, 11Centre ARThrite - CHU de Québec - Université Laval, Quebec, QC, Canada, 12Universidade do Estado do Rio de Janeiro, Rio De Janeiro, Brazil, 13Department of Rheumatology, Endocrinology and Nephrology, Faculty of Medicine and Graduate School of Medicine, Hokkaido University, Sapporo, Japan, Sapporo, Japan, 14Peking University First Hospital, Beijing, China, 15University College London, London, United Kingdom, 16University of Utah and Intermountain Healthcare, Salt Lake City, UT, 17Rheumatology Unit, Azienda USL IRCCS di Reggio Emilia, Reggio Emilia, Italy, 18University of Brescia, Brescia, Italy, 19Mayo Clinic, Rochester, MN, 20Hospital Universitario 12 de Octubre, Madrid, Spain, 21Johns Hopkins University School of Medicine, Timonium, MD, 22Hospital Clinic de Barcelona, Barcelona, Spain, 23Istanbul University, Istanbul Faculty of Medicine, Division of Rheumatology, Istanbul, Turkey, 24CREAR, Rosario, Argentina, 25Department of Rheumatology and lmmunology, Ruijin Hospital, School of Medicine, Shanghai Jiao Tong University, Shanghai, China, Shanghai, China (People's Republic), 26University of Michigan, Ann Arbor, MI, 27University of Texas Medical Branch, Galveston, TX, 28IRCCS Istituto Auxologico Italiano 100%, Cusano Milanino, Milan, Milan, Italy, 29King's College London, London, United Kingdom, 30University College London Hospitals NHS Foundation Trust, London, United Kingdom, 31Division of Rheumatology, Allergy, and Immunology, University of North Carolina, Chapel Hill, NC, 32University of São Paulo, São Paulo, SP, Brazil, 33Hospital for Special Surgery, New York, NY

    Background/Purpose: The APS ACTION Registry was created to study long-term outcomes in persistently antiphospholipid antibody (aPL)-positive patients with and without other systemic autoimmune rheumatic diseases…
  • Abstract Number: 0121 • ACR Convergence 2024

    Intra-renal Involvement in Primary Antiphospholipid Antibodies Syndrome: Data from Two Italian Centers

    Liala Moschetti1, Savino Sciascia2, Micaela Fredi3, Mattia Zappa4, Massimo Radin5, Ilaria Cavazzana3, Stefania Affatato6, Cecilia Nalli7, Laura Andreoli8, Federico Alberici9, Franco Franceschini1, Dario Roccatello10 and Angela Tincani11, 1Scleroderma Unit, Rheumatology and Clinical Immunology Unit, ERN ReCONNET, ASST Spedali Civili, Brescia, Italy, Brescia, Italy, 2University of Turin, Torino, Turin, Italy, 3Rheumatology and Clinical Immunology Unit and Department of Clinical and Experimental Sciences, ERN ReCONNET; ASST Spedali Civili and University of Brescia, Italy, Brescia, Italy, 4Nephrology Unit and Department of Medical and Surgical Specialties, Radiological Sciences, and Public Health; ASST Spedali Civili and University of Brescia, Italy, Brescia, Italy, 5University of Turin, Turin, Italy, 6Nephrology Unit, University of Brescia, ASST Spedali Civili, Brescia, Italy, Brescia, Italy, 7ASST SPEDALI CIVILI DI BRESCIA, Brescia, Italy, 8University of Brescia, Brescia, Italy, 9Nephrology Unit, ASST Spedali Civili di Brescia, Brescia, Italy, 10Nephrology and Dialysis Unit and Center of Immuno-Rheumatology and Rare Diseases (CMID) and Department of Clinical and Biological Sciences; San Giovanni Bosco Hospital and University of Turin, Italy, Turin, Italy, 11ASST Spedali Civili-University of Brescia, Brescia, Italy

    Background/Purpose: Antiphospholipid antibodies nephropathy (aPL-N) is defined by thrombotic microangiopathy (TMA) early lesions and late lesions such fibro-intimal hyperplasia with luminal obliteration/organized thrombi, fibrous arterial/arteriolar…
  • Abstract Number: 0007 • ACR Convergence 2024

    Bromodomain 2 of BET Proteins Plays a Crucial Role in Follicular/peripheral Helper T Cell and Plasma Cell Differentiation

    Ryota Sato1, Mitsuhiro Akiyama2, Koichi Oshita3, Yuko Kawano3, Yuki Imura3, Piruzyan Mariam4, Manami Kikuchi3, Mikako Murase3, Sachiko Mochiduki3, Naohiro Hashimoto3, Masayuki Watanabe3, Keiko Yoshimoto5, Tsutomu Takeuchi6, Kenji Chiba7 and Yuko Kaneko5, 1Mitsubishi Tanabe Pharma Corporation, Brighton, MA, 2Keio University School of Medicine, Palo Alto, CA, 3Mitsubishi Tanabe Pharma Corporation, Yokohama, Japan, 4Mitsubishi Tanabe Pharma Corporation, Yokohama, Kanagawa, Japan, 5Keio University School of Medicine, Tokyo, Japan, 6Department of Internal Medicine, Keio University, Tokyo, Tokyo, Japan, 7Mitsubishi Tanabe Pharma Corporation, Tokyo, Japan

    Background/Purpose: Proteins motifs bromodomain 1 (BD1) and BD2 within the BET family proteins regulate gene expression of inflammatory cytokines and lymphocyte proliferation by binding to…
  • Abstract Number: 0083 • ACR Convergence 2024

    Culturing and Comparative Analysis of Small Intestinal Organoids from SKG and MIFKO-SKG Mice

    Mariia Korshko1, Shaghayegh Foroozan Boroojeni2 and Nigil Haroon3, 1University Health Network, Toronto, ON, Canada, 2UHN, Toronto, Canada, 3Department of Medicine/Rheumatology, University Health Network, Schroeder Arthritis Institute, University of Toronto, Toronto, ON, Canada

    Background/Purpose: Axial Spondyloarthritis (AxSpA) is a chronic inflammatory disease affecting both the joints and gut, with 60% of patients showing microscopic and 10% overt IBD…
  • Abstract Number: 0089 • ACR Convergence 2024

    Single-Cell RNA Sequencing Outlines the Mechanisms of Vgll3-Driven Myofibroblasts Differentiation in Promoting Fibrosis in Cutaneous Lupus

    Mehrnaz Gharaee-Kermani, Allison Billi, Poulami Dey, Jacob Martens, Marisa Hildebrandt, J. Michelle Kahlenberg and Johann Gudjonsson, University of Michigan, Ann Arbor, MI

    Background/Purpose: Skin fibrosis is characterized by collagen deposition, fibro/myofibroblast accumulation, and extracellular matrix remodeling. Some subtypes of cutaneous lupus erythematosus (CLE), particularly discoid lupus erythematosus…
  • Abstract Number: 0105 • ACR Convergence 2024

    Novel Autoantibodies Identified in the Antiphospholipid Syndrome

    Shikai Hu1, Yangzhong Zhou1, Menghua Cai1, Mengtao Li2 and JIULIANG ZHAO1, 1Peking Union Medical College Hospital, Beijing, China, 2Department of Rheumatology and Clinical Immunology, Peking Union Medical College Hospital, Chinese Academy of Medical Sciences, Peking Union Medical College, Beijing, China 2National Clinical Research Center for Dermatologic and Immunologic Diseases (NCRC-DID), Ministry of Science & Technology, Beijing, China

    Background/Purpose: The antiphospholipid syndrome (APS) is a systemic autoimmune disease characterized by arterial, venous, or microvascular thrombosis, recurrent pregnancy morbidity, or non-thrombotic manifestations in the…
  • Abstract Number: 0103 • ACR Convergence 2024

    CD10highLow-Density Granulocytes Is a Potential Marker of Disease Activity in Antiphospholipid Syndrome

    chun Li, Peking University People's Hospital, Beijing, China

    Background/Purpose: To investigate the relationship between CD10highLow-Density Granulocytes (LDG) and disease activity in antiphospholipid syndrome(APS).Methods: This study included 99 patients with APS who were treated…
  • Abstract Number: 0079 • ACR Convergence 2024

    Characterization of the Tissue Resident Memorial T Cells in Autoimmune Arthritis: A Comparative Study of Psoriatic Arthritis and Rheumatoid Arthritis

    Siba Raychaudhuri1, Christine Abria2 and Smriti K Raychaudhuri3, 1UC Davis, School of Medicine/ VA Medical Center, Sacramento, Davis, CA, 2VA Medical Center Sacramento, Mather, CA, 3VA Sacramento Medical Center, Mather, CA

    Background/Purpose: Tissue-resident memory T cells (TRM) cells can drive localized, recurrent inflammation. TRM are site-specific T cells that take up long-term residence in peripheral tissues…
  • Abstract Number: 0085 • ACR Convergence 2024

    A Novel, Potent and Selective TLR7/8 Small Molecule Inhibitor Blocks TLR7/8 Pathway in the Presence of HCQ and Demonstrates Robust Preclinical Efficacy in Lupus Models

    Ching Shang1, Angie Hammond2, Yuanjiang Yu1, Bing Xia1, Yew Ann Leong1, Emily Chung1, zhiyu Huang1, Paqui Gonzalez Traves3, Wesley Minto1, Sunish Mohanan1, Hailing Zong1, Gundula Min-oo1, Stephen Ammann4, Eda Canales5 and Natasha Crellin3, 1Gilead Sciences, Foster City, CA, 2Gilead Sciences, Inc., Seattle, WA, 3Gilead, Foster City, CA, 4Gilead Sciences, Foster City, 5Gilead Sciences, San Mateo, CA

    Background/Purpose: Toll-like receptor 7, 8 and 9 (TLR7/8/9) are endosomal nucleic acid sensors that when aberrantly activated, induce Type I interferon (IFNα), proinflammatory cytokines, immune…
  • Abstract Number: 0086 • ACR Convergence 2024

    Evaluating the Efficacyof B Cell Targeting Drug Candidates Using a Humanized BAFF Transgenic SLE Mouse Model

    Juan Liang, Shuxin Xu, Qiuping Xu and Yuxi Zhang, GemPharmatech, San Diego

    Background/Purpose: B-cell-activating factor (BAFF) plays a critical role in B cell survival, and its elevated expression can contribute to the presence of autoreactive B cells,…
  • Abstract Number: 0092 • ACR Convergence 2024

    A New Generation Mesenchymal Stromal Cell (MSC)-based Cell Therapy Using Design of Experiments Halts Pristane Induced Glomerulosclerosis

    Hulya Bukulmez1, Adrienne Dennis2, kristine Highland3 and Steven N. Emancipator4, 1MetroHealth Medical Center, Case Western Reserve, Pepper Pike, OH, 2MetroHealth Medical Center, Case Western Reserve, Cleveland, OH, 3Cleveland Clinic Foundation, Cleveland, OH, 4Case Western Reserve University, Cleveland, OH

    Background/Purpose: MSCs, exposed to a disease-specific cytokine profile, can accurately sense the composition of the inflammatory microenvironment. We have harnessed this adaptive ability of MSCs…
  • Abstract Number: 0114 • ACR Convergence 2024

    Rare Germline Variants in Complement Regulatory Genes in Antiphospholipid Antibody Positive Patients: Prospective Results from AntiPhospholipid Syndrome Alliance for Clinical Trials and InternatiOnal Networking (APS ACTION) Clinical Database and Repository (“Registry”)

    Cécile Yelnik1, shruti chaturvedi2, Julien Labreuche3, Xiang-Zuo Pan2, H Michael Belmont4, Nina Kello5, Paul Fortin6, David Branch7, Yu Zuo8, Rohan Willis9, Robert Brodsky2, Jane Salmon10, Maria Laura Bertolaccini11, Hannah Cohen12, Michelle Petri13 and Doruk Erkan10, and on behalf of APS ACTION, 1lille university, Lille, France, 2John Hopkins University, Baltimore, MD, 3Lille University Hospital, Lille, France, 4NYU Langone Health, New York, NY, 5Northwell Health, Brooklyn, NY, 6Centre ARThrite - CHU de Québec - Université Laval, Quebec, QC, Canada, 7University of Utah and Intermountain Healthcare, Salt Lake City, UT, 8University of Michigan, Ann Arbor, MI, 9University of Texas Medical Branch, Galveston, TX, 10Hospital for Special Surgery, New York, NY, 11King's College London, London, United Kingdom, 12University College London Hospitals NHS Foundation Trust, London, United Kingdom, 13Johns Hopkins University School of Medicine, Timonium, MD

    Background/Purpose: We previously reported that markers of complement activation, specifically elevated C4d levels and positive modified HAM (mHAM) test, are associated with a higher risk…
  • Abstract Number: 0120 • ACR Convergence 2024

    Vascular Liver Disorders in Patients with Antiphospholipid Syndrome: A Retrospective National Multicentre Study

    Mathilde Katims1, Marc Pineton de Chambrun2, Cecine Yelnik3, Arthur Mageau4, Ada Clarke1, Matthias Papo5, Zahir Amoura6, Marc Lambert3, Thomas Papo4, Laure Delaval7, Pierre-Emmanuel Rautou8, Nathalie Costedoat-chalumeau9 and Karim Sacré4, 1Assistance Publique Hopitaux de Paris, Paris, France, 2Sorbonne Université, Paris, France, 3Université de Lille, Lille, France, 4Université Paris Cité, Paris, France, 5Department of Internal Medicine, Cochin Hospital, National Referral Center for Rare Systemic Autoimmune and Autoinflammatory Diseases of Ile de France, East and West, Paris Cité University, Assistance Publique – Hôpitaux de Paris, Paris, France, 6French National Reference Centre for Systemic Lupus Erythematosus, Pitié-Salpêtrière Hospital, Paris, France, 7Hopital Delafontaine, Saint Denis, France, 8Université Paris Cité, Clichy, France, 9University Paris Cité, Paris, France

    Background/Purpose: Antiphospholipid syndrome (APS) is a thrombo-inflammatory disease propelled by autoantibodies that recognize cell surface phospholipids and phospholipid binding proteins. The result is an increased…
  • « Previous Page
  • 1
  • …
  • 8
  • 9
  • 10
  • 11
  • 12
  • …
  • 2425
  • Next Page »
Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology